Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Hikma Pharmaceuticals ( (GB:HIK) ).
Hikma Pharmaceuticals, through its subsidiary Hikma Finance USA LLC, has announced the issuance of $500 million in 5.125% Guaranteed Notes due in 2030. These notes are expected to be traded on the International Securities Market of the London Stock Exchange, potentially enhancing the company’s financial flexibility and market presence.
The most recent analyst rating on (GB:HIK) stock is a Buy with a £2500.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.
Spark’s Take on GB:HIK Stock
According to Spark, TipRanks’ AI Analyst, GB:HIK is a Outperform.
Hikma Pharmaceuticals’ strong financial performance, coupled with positive corporate events such as credit rating upgrades, contribute significantly to its overall stock score. The company’s stable valuation and technical analysis further support its solid market position.
To see Spark’s full report on GB:HIK stock, click here.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a global pharmaceutical company that operates in the healthcare industry. It focuses on the development, manufacturing, and marketing of a wide range of branded and non-branded generic medicines, catering to various therapeutic areas.
Average Trading Volume: 500,367
Technical Sentiment Signal: Buy
Current Market Cap: £4.36B
See more insights into HIK stock on TipRanks’ Stock Analysis page.